(RTTNews) - scPharmaceuticals Inc. (SCPH) Monday reported positive topline results from the pharmacokinetic study of SCP-111 (furosemide), administered via an autoinjector. The study compared the ...
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the ...
BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient ...
The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental ...
scPharmaceuticals Inc., a pharmaceutical company, announced positive topline results from the pharmacokinetic (PK) study of SCP-111, an investigational, low volume, pH neutral formulation of ...
SCP-111 demonstrated a bioavailability of 107.3% (90% CI: 103.9 - 110.8), achieving the 90% confidence interval limit of 80 to 125 percent Participants that received SCP-111 had similar urine output, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback